Literature DB >> 12796522

Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record.

Marinos C Dalakas, Wayne M Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12796522     DOI： 10.1212/01.wnl.0000074394.15882.83

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  25 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

2.  Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.

Authors:  J N Moy; A M Scharenberg; M R Stein; D Suez; R L Roberts; R J Levy; M Ballow; M B Fasano; C H Dash; S J Leach
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

Review 3.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Safety of IGIV therapy and infusion-related adverse events.

Authors:  Mark Ballow
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

5.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

Review 6.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

Review 7.  Immunoglobulin for multifocal motor neuropathy.

Authors:  Stephen Keddie; Filip Eftimov; Leonard H van den Berg; Ruth Brassington; Rob J de Haan; Ivo N van Schaik
Journal:  Cochrane Database Syst Rev       Date:  2022-01-11

8.  Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block?

Authors:  Neil G Simon; Gretchen Ayer; Catherine Lomen-Hoerth
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

Review 9.  Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Authors:  Jan D Lünemann; Isaak Quast; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up.

Authors:  Andreas Baumann; Christian W Hess; Matthias Sturzenegger
Journal:  J Neurol       Date:  2009-04-09       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.